ABBV-291 is under development for the treatment of relapsed or refractory (R/R) non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and ...
CMN-005 is under clinical development by Benecyte and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 31% phase transition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback